The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic combination, regarding time to psychiatric rehospitalization, in participants with a psychotic disorder (that is, schizophrenia, schizotypal disorders, schizoaffective disorders, persistent or acute or induced or non-organic delusional disorders, recurrent depressive disorder with psychotic symptoms).
Study Type
OBSERVATIONAL
Enrollment
579,728
No intervention will be administered.
Eisai Ltd. European Knowledge Centre
Hatfield, Hertfordshire, United Kingdom
Time from Discharge from a Psychiatric Hospitalization to the Next Psychiatric Rehospitalization
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Percentage of Participants Using Loxapac as Monotherapy or With Other Antipsychotic Polypharmacy Medication
Percentage of participants will be reported using Loxapac or other polypharmacy medications, including anti-psychotic medication (typical/atypical); anti-depressants; anti-psychotic medication sedatives (other than benzodiazepines and z-drugs) and with benzodiazepines and z-drugs; anti-psychotic medication and lithium; anti-psychotic medication mood stabilizers; and with at least one other concomitant medication and without concomitant medication. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants With Consultations Based on a Hospital Psychiatrists, General Practitioner, Private Psychiatric Practitioner or Other Private Specialist
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants With Hepatic, Glycaemia, Cardiovascular, Lipidic Anomalies Assessments
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants With Loxapac Treatment Episodes
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants With Off-drug Loxapac Treatment Period
The off-drug period is defined as the period between two sequences of Loxapac treatment. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Duration of Loxapac Treatment
The time between the start of each Loxapac sequence since the end of Loxapac sequence, switch to another treatment or end of follow-up. Several sequences may exist for one participant. This outcome will be based on medical possession ratio (MPR). MPR will be calculated using B/D formula. Where, B is number of days of supply of Loxapac and D is number of days between the initiation of Loxapac and the end of follow-up. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Percentage of Days Covered (PDC) With Loxapac Treatment
PDC will be calculated using A/D formula. Where A is number of days "covered", that is, number of days of supply of Loxapac without carry-over of overlap days and D is number of days between the initiation of Loxapac and the end of follow-up. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Medical Possession Ratio (MPR)
MPR will be calculated using B/D formula. Where, B is number of days of supply of Loxapac and D is number of days between the initiation of Loxapac and the end of follow-up. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Fixed Medical Possession Ratio (FMPR)
FMPR will be evaluated using MPR and PDC. MPR will be calculated using B/D formula. Where, B is number of days of supply of Loxapac and D is number of days between the initiation of Loxapac and the end of follow-up. PDC will be calculated using A/D formula. Where A is number of days "covered", that is, number of days of supply of Loxapac without carry-over of overlap days and D is number of days between the initiation of Loxapac and the end of follow-up. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants Categorized Based on all Hospitalizations, Psychiatric and Other Hospitalizations
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants With Passage Through Emergency Department of Hospital
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Number of Participants Using Different Antipsychotic Medications
The different antipsychotic medication (other than Loxapac) among the following categories: clozapine, olanzapine, aripiprazole, risperidone, quetiapine, amisulpride, others oral medication. Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Cumulative Duration of Loxapac as Monotherapy
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Cumulative Duration of an Atypical/Typical Antipsychotic Drug Taken as Monotherapy Other Than Loxapac
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Cumulative Duration of Anti-Psychotic Biotherapy
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Cumulative Duration of Loxapac and an Atypical/Typical Antipsychotic Therapy
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Cumulative Duration of Other Antipsychotic Polypharmacy
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020
Cumulative Duration of Periods Without any Antipsychotic Treatment
Participants will be censored in case of death or lost to follow up or on 31 Dec 2020, whichever occurs first.
Time frame: From 1 January 2014 to 31 December 2020